within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01X_OtherAntineoplasticAgents.L01XH01_Vorinostat;

model Vorinostat
  extends Pharmacolibrary.Drugs.ATC.L.L01XH01;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>L01XH01</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Vorinostat is a histone deacetylase inhibitor used as an antineoplastic agent primarily for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have progressive, persistent, or recurrent disease on or following two systemic therapies. It is approved for use in several countries including the United States.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adult patients with advanced cancer after oral administration. Data represent typical values in studied populations.</p><h4>References</h4><ol><li><p>Kavanaugh, SM, et al., &amp; Kolesar, JM (2010). Vorinostat: A novel therapy for the treatment of cutaneous T-cell lymphoma. <i>American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists</i> 67(10) 793–797. DOI:<a href=\"https://doi.org/10.2146/ajhp090247\">10.2146/ajhp090247</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/20479100/\">https://pubmed.ncbi.nlm.nih.gov/20479100</a></p></li><li><p>Rubin, EH, et al., &amp; Iwamoto, M (2006). A study to determine the effects of food and multiple dosing on the pharmacokinetics of vorinostat given orally to patients with advanced cancer. <i>Clinical cancer research : an official journal of the American Association for Cancer Research</i> 12(23) 7039–7045. DOI:<a href=\"https://doi.org/10.1158/1078-0432.CCR-06-1802\">10.1158/1078-0432.CCR-06-1802</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/17145826/\">https://pubmed.ncbi.nlm.nih.gov/17145826</a></p></li><li><p>Kang, SP, et al., &amp; Ratain, MJ (2010). A pharmacogenetic study of vorinostat glucuronidation. <i>Pharmacogenetics and genomics</i> 20(10) 638–641. DOI:<a href=\"https://doi.org/10.1097/FPC.0b013e32833e1b37\">10.1097/FPC.0b013e32833e1b37</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/20729791/\">https://pubmed.ncbi.nlm.nih.gov/20729791</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Vorinostat;
